Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68-DOTATATE vs Ga-68-DOTATOC PET in Meningioma
NCT04298541Phase 2Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2026
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium Ga 68-edotreotide in meningioma, sponsored by Weill Cornell Medicine. Primary endpoints: Qualitative Visual Appearance of Target Lesion to Cranial Blood Pool Using Maximum SUV Ratio at 12 months and Quantitative Visual Appearance of Target Lesion to Cranial Blood Pool Using Maximum SUV Ratio at 12 months. Planned start Aug 2026; status: withdrawn.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT04298541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298541.